ConductScience.org, home

Paper46388

Advanced diffuse histiocytic lymphoma, a potentially curable disease.

DeVita VT and 5 others. Lancet, 1975. Cited by 509 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Papers, record 46388. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/46388

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advanced diffuse histiocytic lymphoma, a potentially curable disease.
PubMed
Journal
Lancet
PubMed
Year
1975
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
509
iCite
Relative citation ratio, by iCite
14.2
iCite
Revised in PubMed
2019-06-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1DeVita VT JrV T
2Canellos GPG P
3Chabner BB
4Schein PP
5Hubbard SPS P
6Young RCR C

Source PubMed

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Lymphoma, Large B-Cell, DiffuseMajor topic
Administration, Oral
Adult
Aged
Biopsy
Cyclophosphamide
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Nitrogen Mustard Compounds
Prednisone
Procarbazine
Remission, Spontaneous
Time Factors
Vincristine

Source PubMed

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00001337Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's LymphomaBackground

Cited by54

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 509 citations.

PMIDTitleJournalYearIn PapersSource
41,747,191Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.Blood Adv2026https://conductscience.org/library/papers/41747191PubMed
39,993,179A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for Lymphoma.Blood Cancer Discov2025https://conductscience.org/library/papers/39993179PubMed
39,049,984Quality of life assessment and cost‑utility analysis of initial chemotherapy for patients with non‑Hodgkin's lymphoma: A prospective analysis.Oncol Lett2024https://conductscience.org/library/papers/39049984PubMed
38,328,609Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018).Cancer Pathog Ther2023https://conductscience.org/library/papers/38328609PubMed
34,807,015DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?Clin Adv Hematol Oncol2021https://conductscience.org/library/papers/34807015PubMed
33,466,277NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.Cancers (Basel)2021https://conductscience.org/library/papers/33466277PubMed
32,496,453Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma.Cancer J2020https://conductscience.org/library/papers/32496453PubMed
29,531,285Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.Blood Cancer J2018https://conductscience.org/library/papers/29531285PubMed
28,683,298Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.Cell Metab2017https://conductscience.org/library/papers/28683298PubMed
27,568,520Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.Leukemia2017https://conductscience.org/library/papers/27568520PubMed
26,969,332Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort.Eur J Health Econ2017https://conductscience.org/library/papers/26969332PubMed
26,355,399A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma.Sultan Qaboos Univ Med J2015https://conductscience.org/library/papers/26355399PubMed
26,248,897Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.Mod Pathol2015https://conductscience.org/library/papers/26248897PubMed
25,501,975Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy.Ann Hematol2015https://conductscience.org/library/papers/25501975PubMed
24,338,592Modelling lymphoma therapy and outcome.Bull Math Biol2014https://conductscience.org/library/papers/24338592PubMed
24,217,204Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Nat Rev Clin Oncol2014https://conductscience.org/library/papers/24217204PubMed
24,212,956Assessment of the evolution of cancer treatment therapies.Cancers (Basel)2011https://conductscience.org/library/papers/24212956PubMed
23,086,603Diffuse large B cell lymphoma: molecular targeted therapy.Int J Hematol2012https://conductscience.org/library/papers/23086603PubMed
22,305,028My treatment approach to patients with diffuse large B-cell lymphoma.Mayo Clin Proc2012https://conductscience.org/library/papers/22305028PubMed
20,011,310Colorectal lymphoma.Clin Colon Rectal Surg2006https://conductscience.org/library/papers/20011310PubMed

See all 54 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/46388

GET https://conductscience.org/api/papers/v1/46388/cited_by?page=2